Up until recently, insulin pumps didn’t change that much - they did basal, they did bolus, and that was about it, so the typical 4-year insurance company reimbursement cycle wasn’t really a big deal.
But the pace of innovation in diabetes technology has picked up rapidly. Between 2012 and 2017, Tandem Diabetes Care® alone has launched 6 different products…
Evaluating pumps for your diabetes management can be a nerve-wracking decision. You have a lot more things to consider than ever before.
How do you balance having the best technology today with the fear of missing out on some important breakthrough that could be right around the corner?
What if you could choose a pump today that could be updated with new features as they become approved and available?
Now you can!
Upon FDA approval of Dexcom G5 Mobile CGM compatibility, thousands of existing t:slim X2™ Pump users were able to add CGM integration to their pump from home using their personal computer without waiting for their insurance to cover a new device.
A lot can happen in four years.
Features identified in this video are examples of pump features which may be available or under development in the market generally and do not necessarily reflect features currently available, or which may become available for Tandem pumps. Available software updates for Tandem pumps can be found at www.tandemdiabetes.com/updater. Additional software updates and new features are subject to future FDA approvals. Charges may apply.
RX ONLY. The t:slim X2 Insulin Pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The t:slim X2 Insulin Pump can be used solely for continuous insulin delivery and as part of the t:slim X2 System to receive and display continuous glucose measurements from the Dexcom G5 Mobile Sensor and Transmitter. The t:slim X2 System also includes continuous glucose monitoring (CGM) indicated for the management of diabetes. The Dexcom G5 Mobile CGM is designed to replace fingerstick blood glucose testing for diabetes treatment decisions. The t:slim X2 System aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments, which may minimize these excursions. Interpretation of the t:slim X2 System results should be based on the trends and patterns seen with several sequential readings over time. The t:slim X2 System is indicated for use in individuals 6 years of age and greater. The t:slim X2 System is intended for single patient use and requires a prescription. The device is indicated for use with NovoLog or Humalog U-100 insulin.
© 2017 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc. Dexcom and Dexcom G5 are registered trademarks of Dexcom, Inc.